Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker AYTU
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Lytton-Kambara Foundation | 545,946 | 5.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Laurence W. Lytton | 545,946 | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Lytton-Kambara Foundation | 895,528 | 8.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Laurence W. Lytton | 1.07M | 10.0% | SCHEDULE 13G/A ↗ |
| Feb 13, 2026 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | AWM Investment Company, Inc. | 619,574 | 5.8% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Lytton-Kambara Foundation | 1.09M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Laurence W. Lytton | 1.09M | 10.0% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | David Kanen | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Kanen Wealth Management LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Philotimo Focused Growth & Income Fund | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 12, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Philotimo Fund, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | AWM Investment Company, Inc. | 619,874 | 6.9% | SCHEDULE 13G ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Jon M. Plexico | 906,063 | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Stonepine GP, LLC | 906,063 | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Stonepine Capital, L.P. | 906,063 | 9.9% | SCHEDULE 13G/A ↗ |
| Aug 13, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Stonepine Capital Management, LLC | 906,063 | 9.9% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | David Kanen | 573,358 | 6.4% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Kanen Wealth Management LLC | 573,358 | 6.4% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Philotimo Focused Growth & Income Fund | 189,208 | 2.1% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Philotimo Fund, LP | 384,150 | 4.3% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | David Kanen | 166,268 | 2.7% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Kanen Wealth Management LLC | 166,268 | 2.7% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Philotimo Focused Growth & Income Fund | 54,868 | 0.9% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Philotimo Fund, LP | 111,400 | 1.8% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | David Kanen | 635,073 | 10.3% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Kanen Wealth Management LLC | 635,073 | 10.3% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Philotimo Focused Growth & Income Fund | 209,573 | 3.4% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G/A (amended) | AYTU Aytu BioPharma, Inc. | Philotimo Fund, LP | 425,500 | 6.9% | SCHEDULE 13G/A ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | David Kanen | 381,805 | 6.2% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Kanen Wealth Management LLC | 381,805 | 6.2% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Philotimo Focused Growth & Income Fund | 125,995 | 2.0% | SCHEDULE 13G ↗ |
| Jun 26, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Philotimo Fund, LP | 255,810 | 4.1% | SCHEDULE 13G ↗ |
| Jun 13, 2025 | SCHEDULE 13G | AYTU Aytu BioPharma, Inc. | Laurence W. Lytton | 506,605 | 5.6% | SCHEDULE 13G ↗ |
| Jun 9, 2025 | SCHEDULE 13D/A (amended) | AYTU Aytu BioPharma, Inc. | Mack Daniel | 1.09M | 14.4% | SCHEDULE 13D/A ↗ |
| Jun 9, 2025 | SCHEDULE 13D/A (amended) | AYTU Aytu BioPharma, Inc. | Wilmot B. Harkey | 1.09M | 14.4% | SCHEDULE 13D/A ↗ |
| Jun 9, 2025 | SCHEDULE 13D/A (amended) | AYTU Aytu BioPharma, Inc. | Nantahala Capital Management, LLC | 1.09M | 14.4% | SCHEDULE 13D/A ↗ |
36 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 10:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances